SuperGen Presentations at AACR-NCI-EORTC
|
|
|
| Posted
:
Mon, 09 Nov 2009 11:02:00 GMT |
| Author
:
SuperGen, Inc.
|
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
| Press Release
News |
Home
|
|
|
|
DUBLIN, Calif. - (Business Wire) SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA. SuperGen’s presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776, SGI-110, SGI-1252, as well as two presentations on the Etk program. The posters will be made available for viewing on the company’s website www.supergen.com following the respective presentations. | MP-470: The tyrosine kinase inhibitor MP470 inhibits RAD51-mediated homologous recombination and increases tumor cell radio- and chemosensitivity | | Abstract A122, Monday Nov 16, 12:30 – 2:30 pm EST | | | | SGI-110: In vivo activity of SGI-110, a novel hypomethylating agent for treatment in hematology and solid malignancies | | Abstract A190, Monday Nov 16, 12:30 – 2:30 pm EST | | | | MP-470: A self-emulsifying lipid suspension formulation enhances oral bioavailability of MP-470 in a randomized two-way crossover study in healthy male subjects | | Abstract B209, Tuesday Nov 17, 12:30 – 2:30 pm EST | | | | SGI-1776: The novel PIM kinase inhibitor SGI-1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma | | Abstract B272, Tuesday Nov 17, 12:30 – 2:30 pm EST | | | | ETK/BMX: Mechanistic, functional and in vivo efficacy of inhibiting ETK/BMX in cancer models | | Abstract B263, Tuesday Nov 17, 12:30 – 2:30 pm EST | | | | SGI-1252: In vivo activity of SGI-1252, a potent, small-molecule dual inhibitor of JAK2 and ALK2 | | Abstract C206, Wednesday Nov 18, 12:30 – 2:30 pm EST | | | | ETK: Development of potent, small-molecule inhibitors of ETK | | Abstract C199 Wednesday Nov 18, 12:30 – 2:30 pm EST | About SuperGen SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com.
SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Development
tenns@supergen.com
Susanna Chau, 925-560-2845
Manager
Investor Relations
schau@supergen.com
|
Copyright © 2008
Business Wire. All rights reserved.
|
|
|
|
|
Related
News
DocBuilder.com Provides Legal Forms and Documents for Less
DocBuilder.com is offering 20% of its normal prices for the entire month of December as a way to say, "thanks" to everyone for making 2009 a record setting year. DocBuilder.com makes preparing legal documents inexpensive and easy for everyone. DocBuilder.com provides legal forms and...
us-blackjack.com Launches Exciting New Video Slot
LONDON -
us-blackjack.com
has today announced the launch of “Viking and Striking&rd
Press release: Ahold to sponsor Stedelijk Museum, Amsterdam
AMSTERDAM, NETHERLANDS -- 11/26/09 --
Amsterdam, The Netherlands - Ahold and the Stedelijk Museum have
agreed to enter a three-year sponsorship agreement. Dutch-based
Ahold, which operates supermarket companies in Europe a..
Metso to deliver new environmental waste gasification technology to Lahti Energia Oy in Finland
HELSINKI, FINLAND -- 11/26/09 --
Metso Corporation's press release on November 26, 2009 at 12:00 a.m.
local time
Metso will supply a waste gasification plant to Lahti Energia Oy in
Lahti, Finland. Metso's supply includes w..
Sureyya Ciliv Receives 'CEO of the Year' Award at the 2009 World Communication Awards
ISTANBUL, Turkey, November 26 -- Turkcell (NYSE:
TKC, ISE: TCELL), the leading technology and communications company in
Turkey, announced today that its Chief Executive, Sureyya Ciliv, was last
...
Research and Markets: 2009 Plimsoll Analysis - Consulting Engineers - A Comprehensive Profile of 1000 Companies Operating in the UK Market
DUBLIN -
Research and Markets (
Ryland Oil Announces Agreements to Purchase Eternal Energy Corporation and to Purchase Royalty
VANCOUVER, BRITISH COLUMBIA -- 11/26/09 --
Ryland Oil Corporation ("Ryland" or "the Company") (TSX VENTURE: RYD) is pleased to announce the following:
Agreement to Acquire Eternal Energy Corporation
Ryland and Eternal Energy Cor..
|
|
|
|
|
|
|
|
|
